• Overview
  • Eligibility
  • More info
  • Locations

A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients (NCT00003883)

National Cancer Institute (NCI)
RATIONALE: Giving itraconazole or fluconazole may be effective in preventing infections in patients undergoing peripheral stem cell or bone marrow transplantation. It is not yet known whether itraconazole is more effective than fluconazole for preventing infections. PURPOSE: Randomized phase III trial to compare the effectiveness of itraconazole with fluconazole to prevent infections in patients undergoing peripheral stem cell or bone marrow transplantation.
  • Drug: fluconazole
    • Drug: itraconazole
      Ages eligible for Study
      13 Years and older
      Genders eligible for Study
      All
      Accepts Healthy Volunteers
      No
      OBJECTIVES: I. Compare the efficacy of itraconazole versus fluconazole in reducing the incidence of breakthrough Aspergillus infections in patients undergoing allogeneic peripheral blood stem cell or bone marrow transplantation. II. Compare the incidence of combined mold/yeast infections and the use of alternative systemic antifungal treatments in these patients on this regimen. III. Compare the toxic effects of these two drugs in these patients. IV. Determine the survival rate of these patients.

      OUTLINE: This is a randomized study. Patients are randomized to one of two treatment arms. Arm I: Patients receive fluconazole orally or IV daily beginning at start of conditioning regimen and continuing until day 180 or until 4 weeks after stopping corticosteroids (if it occurs between days 120-180). Arm II: Patients receive oral fluconazole daily beginning at start of conditioning regimen and continuing until day 0. Patients then receive itraconazole orally or IV daily beginning on day 0 and continuing until day 180, or until 4 weeks after stopping corticosteroids (if it occurs between days 120-180).

      PROJECTED ACCRUAL: A total of 578 patients (289 per arm) will be accrued for this study within 4 years.

      2 locations

      United States (2)
      • Fred Hutchinson Cancer Research Center
        Seattle, Washington, United States, 98109-1024
      • University of Washington Medical Center
        Seattle, Washington, United States, 98195-6043
      Status:
      completed
      Type:
      Interventional
      Phase:
      Start:
      30 September, 1998
      Updated:
      30 March, 2010
      Participants:
      578
      A girl giving information about available additional trials.

      FindMeCure helps you find, understand and join clinical trials from all over the world.

      There are more clinical trials for your condition!